Published on January 20, 2010 at 2:53 AM
Rexahn Pharmaceuticals, Inc. (NYSE Amex:RNN), a clinical stage
pharmaceutical company commercializing potential best in class oncology
and CNS therapeutics, today announced that the European Patent Office
has granted a patent for its novel anti-cancer compound, RX-3117.
“In addition to our co-development partnership with Teva, this European
patent award further validates the commercial potential of RX-3117”
“In addition to our co-development partnership with Teva, this European
patent award further validates the commercial potential of RX-3117,”
said Dr. Chang Ahn, Rexahn's Chairman and Chief Executive Officer. “The
development of RX-3117 strengthens our oncology pipeline, which includes
ArchexinTM, currently in Phase II clinical trials.”
RX-3117 is a small molecule, new chemical entity (NCE), nucleoside
compound that inhibits DNA methyltransferase, a cyclin-dependent kinase,
and DNA synthesis. Potential indications of RX-3117 are solid tumors
including colon, lung and pancreatic cancers. In preclinical trials,
RX-3117 has demonstrated its ability to overcome cancer drug resistance
in cancer cells, in particular, gemcitabine-resistance in the human lung
cancer cell. The US patent issued for RX-3117 claims composition of
matter, synthesis, and methods (2008).
In September 2009, Rexahn announced a commercialization and development
agreement with Teva for RX-3117. Under the agreement, Rexahn will be
eligible to receive additional development, regulatory and sales
milestone payments and royalties on net sales worldwide.
Source: Rexahn Pharmaceuticals, Inc.